"Cytochrome P-450 CYP2D6" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P450 enzyme that catalyzes the hydroxylation of many drugs and environmental chemicals, such as DEBRISOQUINE; ADRENERGIC RECEPTOR ANTAGONISTS; and TRICYCLIC ANTIDEPRESSANTS. This enzyme is deficient in up to 10 percent of the Caucasian population.
| Descriptor ID |
D019389
|
| MeSH Number(s) |
D08.244.453.005.600 D08.244.453.491.372 D08.811.682.690.708.170.010.600 D08.811.682.690.708.170.450.368 D12.776.422.220.453.010.600 D12.776.422.220.453.491.368
|
| Concept/Terms |
Cytochrome P-450 CYP2D6- Cytochrome P-450 CYP2D6
- CYP2D6, Cytochrome P-450
- Cytochrome P 450 CYP2D6
- P-450 CYP2D6, Cytochrome
- Sparteine Monooxygenase
- Monooxygenase, Sparteine
- Cytochrome P450 2D6
- P450 2D6, Cytochrome
- Debrisoquine 4-Monooxygenase
- 4-Monooxygenase, Debrisoquine
- Debrisoquine 4 Monooxygenase
- Imipramine 2-Hydroxylase
- 2-Hydroxylase, Imipramine
- Imipramine 2 Hydroxylase
- CYP2D6
- CYP 2D6
- Debrisoquine 4-Hydroxylase
- 4-Hydroxylase, Debrisoquine
- Debrisoquine 4 Hydroxylase
- Debrisoquine Hydroxylase
- Hydroxylase, Debrisoquine
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP2D6".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP2D6".
This graph shows the total number of publications written about "Cytochrome P-450 CYP2D6" by people in this website by year, and whether "Cytochrome P-450 CYP2D6" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytochrome P-450 CYP2D6" by people in Profiles.
-
CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy. Cancer Causes Control. 2019 Jan; 30(1):103-112.